Novo Nordisk Cuts Wegovy Price to Combat Competition
Tap title to read story
Novo Nordisk announced a price reduction for its weight-loss drug Wegovy to $499 per month for uninsured patients, delivered to their homes. This follows Eli Lilly's recent price cut for its competitor, Zepbound. The move aims to undercut compounding pharmacies that have been selling cheaper copies of Wegovy, which the FDA recently removed from its shortage list. Novo Nordisk's stock price rose following the announcement, while that of a telehealth company selling compounded Wegovy fell.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.